It’s Time for Us to Think About Cancer Differently

“It’s Time for Us to Think About Cancer Differently.” By Paula Mejia, Newsweek.

Cancer is typically classified by where the cancerous tissues originated—so cells clustering in the lungs are called “lung cancer,” and those in the throat are “throat cancer.” But many kinds of cancer affect more than one kind of tissue, which can . . . → Read More: It’s Time for Us to Think About Cancer Differently

Study Shows Third Gene as Indicator for Breast Cancer

“Study Shows Third Gene as Indicator for Breast Cancer.” By Nicholas Bakalar, The New York Times.

Mutations in a gene called PALB2 raise the risk of breast cancer in women by almost as much as mutations in BRCA1 and BRCA2, the infamous genes implicated in most inherited cases of the disease, . . . → Read More: Study Shows Third Gene as Indicator for Breast Cancer

I Had My DNA Picture Taken, With Varying Results

“I Had My DNA Picture Taken, With Varying Results.” by Kira Peikoff, The New York Times.

In recent years, a handful of studies have found substantial variations in the risks for common diseases predicted by direct-to-consumer companies. I set out to test the tests: Could three of them agree on me? The answers were . . . → Read More: I Had My DNA Picture Taken, With Varying Results

Reflections on FDA Warning to 23andMe

“Reflections on FDA Warning to 23andMe.” by Jim Evans, The Cancer letter.

There’s been much recent gnashing of teeth (at least within the narrow and rather insular world of do-it-yourself genomics) about the gall of the FDA in choosing to issue a warning letter to 23andMe, effectively shutting down marketing of their direct-to-consumer personal genomic . . . → Read More: Reflections on FDA Warning to 23andMe

Regulation Expert Weighs In on FDA Letter to 23andMe

“Regulation Expert Weighs In on FDA Letter to 23andMe.” Mendelspod.com.

On Monday, November 25th, the FDA sent a letter to the direct-to-consumer genetic testing company, 23andMe. The letter has received a bit more attention than the average FDA correspondence. The letter was addressed to 23andMe CEO, Anne Wojcicki, and told her that the company’s Personal . . . → Read More: Regulation Expert Weighs In on FDA Letter to 23andMe

In Israel, a Push to Screen for Cancer Gene Leaves Many Conflicted

“In Israel, a Push to Screen for Cancer Gene Leaves Many Conflicted” By Roni Caryn Rabin, The New York Times.

KFAR SABA, Israel — Ever since she tested positive for a defective gene that causes breast cancer, Tamar Modiano has harbored a mother’s fear: that she had passed it on to her two daughters. . . . → Read More: In Israel, a Push to Screen for Cancer Gene Leaves Many Conflicted

Yale Genetic Counselor Weighs in on Myriad Case and More: Ellen Matloff

“Yale Genetic Counselor Weighs in on Myriad Case and More: Ellen Matloff.” Published by Ayanna Monteverdi, Mendelspod.com.

The first genetic counselor at Yale’s School of Medicine, Ellen Matloff has had a front row seat to the long saga of gene patents, particularly the BRCA patents of Myriad Genetics. In today’s interview Ellen recalls the days . . . → Read More: Yale Genetic Counselor Weighs in on Myriad Case and More: Ellen Matloff

Book Review: Am I My Genes? Confronting Fate and Family Secrets in the Age of Genetic Testing

Robert Klitzman’s “Am I My Genes?” explores a key question facing individuals in a genetic age: How does my genetic profile shape who I am and, in turn, what I believe? In-depth interviews with 64 people who have, or are at risk for, three diseases with identified genetic components (i.e., Huntington’s disease, breast and . . . → Read More: Book Review: Am I My Genes? Confronting Fate and Family Secrets in the Age of Genetic Testing

A Genetic Counselor Explains How Gene Patents Harmed Her Patients

“A Genetic Counselor Explains How Gene Patents Harmed Her Patients.” By Ellen Matloff, MS, Yale Cancer Center, Breast Cancer Action.

Editor’s Note: On July 13, 2013, the Supreme Court ruled in our favor to overturn Myriad Genetics’ patents on the “breast cancer genes,” BRCA1 and BRCA2. We were proud to be the only breast cancer . . . → Read More: A Genetic Counselor Explains How Gene Patents Harmed Her Patients

Our Genes, Their Secrets

“Our Genes, Their Secrets.” By Eleonore Pauwels, The New York Times.

The Supreme Court’s unanimous ruling last Thursday, barring patents on human genes, was a wise and balanced decision that clears away a major barrier to innovation in the areas of biotechnology, drug development and medical diagnostics. But the decision is just a first step . . . → Read More: Our Genes, Their Secrets

Articles & Posts